The ‘Mighty Mouse’ Model in experimental cardiac transplantation
Tissue rejection remains a major problem in organ transplantation. The use of experimental animal models continues to enhance our understanding of the rejection process and offers strategies for its prevention. The popular mouse model of heterotopic cardiac transplantation has been used for over three decades to help investigators understand the pathogenesis of graft rejection and in turn, how novel drugs can attenuate the immune response to transplanted organs. Also, since the genetic blueprint of mice is well-known, specific genes can be modified to study their affect on graft acceptance and tolerance. This review briefly outlines what is known about the unique physiology, haemodynamics and dynamic morphology of the transplanted mouse heart, with particular emphasis on insights gleaned from hi-resolution ultrasound. Current applications and methods to assess rejection are also discussed.
Experimental Animal Models of Transplantation
The translation from theoretical frameworks to clinical transplantation as an established and effective therapy for end-stage organ failure has been possible through extensive scientific insight gained from experimental animal models (1). The French surgeon Alexis Carrel was the first to develop surgical procedures for experimental transplantation and his inaugural work on establishing vascular procedures for kidney and heart transplantation in dogs was recognized with the Nobel prize award in 1912. Poor outcomes in clinical organ transplant surgery made in the late 1930’s were followed by a renewed interest in the early 1960’s due to the production of a novel immunosuppressant, 6-mercaptopurine and subsequently, cyclosporine in 1972. The improved survival rates of transplant patients led to increasing numbers of interested clinicians and researchers in the field, and naturally led to the development of more sophisticated animal models to investigate basic lines of enquiry in transplantation. These include new pharmacological agents capable of mitigating immune responses towards allografts, effective preservation solutions, elucidating immunological mechanisms of rejection and tolerance, developing novel sources of grafts (xenografts), and the establishment of post-transplant monitoring protocols (1-9).
Heterotopic Vascularized Cardiac Grafts in Rodents
Heterotopic transplantation was used as early as the 1940’s and 50’s in large animals but it wasn’t until work by Abbott et al. in 1964 that the heterotopic heart transplantation (HHTX) was perfomed in rodents; the authors used rats and utilized end-to-end anastomosis of the donor thoracic aorta to the recipient abdominal aorta and donor pulmonary artery to recipient inferior vena cava (IVC) (10). Abbott’s procedure resulted in restricted blood flow to the lower extremities and consequently, paraparesis and paraplegia (1). This procedure was revised by Ono and Lindsey to allow for greater blood flow to the lower extremities and employed end-to-side anastomoses of the donor vessels to the recipient aorta and IVC, resulting in 90% graft and recipient survival (11). Heterotopic cervical transplantation was performed in rats in 1971 (12) and required the anastomosis of the recipient external jugular vein and common carotid artery to the donor aorta and pulmonary artery, though thrombosis occurred in 30% of subjects (1). In 1973, Corry et al. were investigating the role of MHC molecules in cardiac graft rejection and concurrently reported performing the HHTx protocol in mice using the same technique established by Ono and Lindsey in the rat (13). Blood flow directionality in this model has been verified using ultrasound biomicroscopy (UBM) and is illustrated in Figure 1 (14). Briefly, blood from the recipient abdominal aortic circulation flows retrograde into the donor graft ascending aorta. In the presence of a competent aortic valve this will direct blood into the coronary arteries to perfuse the cardiac graft; the venous blood then drains into the right atrium via the coronary sinus. Blood then fills the right ventricle which is ejected through the pulmonary artery and enters into the recipient IVC (15). Thus, the model represents a left ventricular bypass with omission of normal pulmonary circulation for blood reoxygenation. Rat HHTx graft blood flow volume comprises about 5% of total blood volume per minute (16).
In experimental cardiac transplantation, rats and mice are the most commonly used animals, though canine, swine, primates and other rodents have also been employed (1). Vascularized heterotopic (abdominal) heart grafting is the method of choice in rodent transplantation and new surgical techniques are being developed to improve survival and reduce complications (17, 18). Xenotransplant models also exist for various inter-species combinations (e.g., rat -> mouse; pig -> monkey) (8, 19, 20).
Vascularized vs. Non-Vascularized Grafts
Primarily or fully vascularized allografts perfused by blood from the recipient circulation, such as kidney, liver, and heart, have many advantages over non-vascularized transplants such as skin allografts, in investigating mechanisms of graft susceptibility to rejection and tolerance induction (21). It is well documented that non-vascularized grafts are subject to non-specific ischemic degeneration that can lead to inflammation and necrosis, even in isografts, which can render them susceptible to subsequent immune rejection (22). However, vascularity alone has been shown to be insufficient to explain the predisposition for non-vascularized grafts to reject faster than vascularized ones (23). One explanation is the presence of tissue-specific antigens. Work by Steinmuller et al. have shown that in hemopoietic chimeras, allogeneic hemopoietic cells survived indefinitely but would not accept skin grafts from the same donor, suggesting that the skin expressed antigens not found on the hemopoietic cells (24). Other important factors to consider are the number and type of antigen presenting cells present in the graft; skin has an abundant number of Langerhans cells — professional antigen presenting cells — which have the capacity to migrate from the graft and efficiently stimulate a large number of alloreactive T cells (25). Finally, the physical size of the graft may also be a determinant in allograft rejection susceptibility; a larger graft or several grafts implanted to the same recipient have a greater total number of cells and thus, require more time for immunological destruction before graft failure ensues (26).
Advantages and Disadvantages of Using the HHTx Murine Model in Transplant Research
Since the HHTx rodent model does not possess venous return to the graft, only limited comparisons can be made with the physiology of the native heart. The use of orthotopic grafts in rodents have been limited in the past due to lack of availability of cardiopulmonary bypass systems for these small animals, particularly mice, however, newer surgical techniques appear to enable transplanted hearts to have normal blood flow direction that approximate the native mouse heart (27). Furthermore, there are numerous studies employing the murine model in gaining translational insight into long-term graft changes that are clinically relevant, such as the development of graft vasculopathy, though these will not be discussed further (28-30).
Though the mouse abdominal HHTx model is a non-physiologic, non-loaded heart model due to the unique directionality of intra-cardiac blood flow (31), it is still valuable in investigating a wide variety of transplant-related issues (32, 33). The benefits of the model include: lower maintenance and surgical costs, limited number of personnel required, availability of a plethora of genetically inbred lines, and isolation and characterization of the MHC molecules in congenic inbred murine lines (1). Studies on MHC molecules form the foundation for understanding immune-mediated responses to allografts. The mouse model also provides important information on graft ischemia-reperfusion injury, rejection pathogenesis, specific reagents for detailed examination of the immunopathology of allograft rejection, immune modulating agents and immunosuppressants, and the physiologic changes that take place post-transplant in vascularized organs (1, 7, 34-38).
Experimental Applications of the HHTx Mouse Model
Rodent heterotopic models of transplantation have been previously used to investigate the efficacy of novel preservation (39) and cold cardioplegia solution (40) as well as to determine the extent of myocardial injury subsequent to hyperkalemic cardioplegia and prolonged hypothermic ischemia (41). McGregor et al. have demonstrated, for example, the beneficial effects of St. Thomas’ cardioplegia solution in augmenting myocardial protection (40). The University of Wisconsin solution (UW lactobionate) has also been evaluated in HHTx rodent models to determine the degree of cardiac injury (39, 42). Other solutions studied include 0.9% saline, lactated Ringer’s and cold solution (43). First glimpses into ischaemic times were also gleaned from rodent studies and continue to offer beneficial information translatable to clinical practise (44-46).
Graft Surveillance and Rejection
HHTx rat and mouse models are widely applied for immunologic and histological studies (35, 47-49). Investigation of effector mechanisms of graft-infiltrating cells by utilizing rat and mouse models of adoptive transfer followed by HHTx surgery has led to a wealth of information regarding immunopathological mechanisms. A sample of the literature includes: determining the critical role of CD4+ and CD8+ T lymphocytes in stimulating graft rejection and their mechanistic roles (50-52); the potential therapeutic effect of antagonism of chemokine (CCR5) and chemokine receptors (CXCR3) in inhibiting both acute and chronic allograft rejection (48); understanding the association of increased Fas ligand mRNA expression with myocardial apoptosis and ischemia-reperfusion injury and the eventual progression to chronic rejection (53); and studying the post-transplant shift in expression of genes classified as defense, communication, and metabolism during the graft response to transplantation injury and rejection (54). For further reading on this large topic, a recent review by Wehner et al. is worth consulting (55).
Pharmacological Testing and Immunosuppression
A number of pharmacological agents have been tested in rodent HHTx models for safety and efficacy prior to studies in larger animals and validation to clinical trials. A few examples include Cyclosporin A (7), pioglitazone (35), sirolimus/rapamycin (5), and mycophenolate mofetil (56). Other studies, such as Mitsuhashi et al.’s, have used gene therapy to induce xenograft tolerance and provided the first demonstration of permanent survival of alphaGal+ hearts following transplantation with autologous bone marrow transduced with porcine GalT-expressing lentivirus (57). Co-stimulatory blockade antibodies (58), genetically engineered dentritic cells (59) and other agents (60) have also been used to induce cardiac allograft tolerance in the mouse and rat. Finally, several monoclonal antibodies targeting molecular epitopes expressed on vascular endothelium and activated T cells have been utilized to induce tolerance and/ or improve long-term graft viability; these include intercellular adhesion molecule-1 (61), lymphocyte function associated antigen and vascular cell adhesion molecule (62).
Cordant and discordant xenograft rejection have been studied in several common species combinations, such as mouse->rat, hamster->rat, guinea pig->rat and hamster-> guinea pig, to examine the efficacy of immunosuppressive drugs (63), total lymphoid irradiation, antibodies (64), and inflammatory mediators (65) in settings of accelerated and hyperacute rejection.
Gene Knock-out and Transgenic Models
With the advent of the genomics and proteomics era, specific gene knock-out and transgenic models have now become available, and are currently being produced in the mouse model (50, 66-68). These developments include transgenic single T-cell receptor (TCR)/peptide/major histocompatibility complex molecule models (50), tran-scriptional regulator class II transactivator deficient mice (66), CD40 ligand knock-out mice (67), and IL-4 deficient mice (68), to name a few. The vast array of possibilities, which are plentiful in literature, have paved the way for molecular biologists, clinical biochemists, and transplant scientists to elucidate specific gene-protein pathways and the components of the immune system that are implicated in the rejection process.
Dynamic Graft Gene Expression
Changes in gene expression post-transplant have been assessed in transplanted mice using DNA microarrays. Work by Christopher et al. used dendrograms and self-organizing maps to determine the differences between isograft and allograft gene expression profiles (classified broadly into defence, communication and metabolism genes) and confirmed by real-time PCR (54, 69). The authors’ results, which are beyond the scope of this review, demonstrated the temporal pattern of gene expression of grafts in response to transplantation injury and rejection.
Assessing HHTx Graft Rejection in the Mouse and Rat
Palpation and Histology
Two common methods for assessing graft function in rat and mouse HHTx models employ finger palpation of cardiac contractions (13, 70) and histology (71, 72). The finger palpation method uses a subjective scale where an observer scores the force of contraction from ‘0’ (cessation of graft contraction) to ‘4’ (vigorous graft contraction). Several criticisms of this method of assessment include its subjectivity, insensitivity in detecting early changes post-transplant (PTx), and poor evaluation of long-term graft survival (73). The ‘gold standard’ for diagnosing rejection clinically and experimentally remains histology (46, 74, 75). Biopsies however are limited by their invasiveness, the patchy nature of cellular infiltration and tissue necrosis (76- 78) and are not feasible for serial studies in mice and rodents due to the small size of the rodent heart (14).
Electrocardiography has been performed in anaesthetized animals with needle electrodes inserted subcutaneously in the abdomen and limbs of the rat (71) and mouse (79). Early attempts reported an accurate determination of graft rejection though high graft heart rates (350-450 BPM) and poorly defined S-T segments precluded consistent interpretation (80). More recently, analysis of total power of heart rate variability was found to be significantly higher in acutely rejecting rat HHTx grafts when compared to isografts (81) using an abdominally-implanted telemetric ECG radio-transmitter. In mouse HHTx studies, allografts were rejected in 10-14 days and showed a rapid fall in palpated heart rate, measured heart rate, and ventricular QRS complex voltage (73). The major limitation of ECG is the possibility that the trace can be affected by the location of abdominal electrodes. This complication is compounded by the lateral and horizontal movements of the graft within the abdomen (73) and interference from surrounding structures such as the intestines and perigraft effusion (14).
Nuclear Magnetic Resonance (NMR) and Related Applications
NMR imaging has been used for pre-clinical investigations evaluating myocardial metabolism during rejection in rat HHTx grafts (82). Haug et al. found that rejecting grafts showed relatively low levels of phosphocreatinine and high levels of inorganic phosphate versus isograft controls (82, 83). More recent efforts have used magnetic resonance imaging (MRI) to measure reduction in MR signal intensity in allografts versus isografts following injection of dextran-coated ultrasmall superparamagnetic iron oxide particles, which was confirmed to be due to macrophage uptake of these particles. The reduction in intensity was also reversible with immunosuppression (84). Other MR-based approaches have been investigated to assess morphological and physiologic changes in rat HHTx grafts, such as the degree of edema, ventricular mass and volume changes, SV, %EF, and LV chamber dimensions, but have not yet been validated for wide-scale experimental use (85). NMR-based approaches have several limitations, however, which include the need for highly technical protocols, very costly equipment, its invasiveness, and the inherent inability in obtaining serial data in the same animal subject in perfusion studies. MRI is also a less desirable option for mice, whose haemodynamic status can be significantly altered by the imaging procedure and its utilization of deep or prolonged anaesthesia (83, 86).
Molecular and Biochemical Markers of Cardiac Graft Rejection
There is a large body of work focused on scintigraphy in detecting cardiac allograft rejection in mouse and rat HHTx models. Previous studies have employed various isotopes and targets to study the effects of acute rejection on radiotracer uptake. These include 123iodine-labeled and 111In anti-ICAM-1 mAbs (87, 88), 111In-labeled anti-MHC class II antigen mAbs (88), and 111In-antimyosin mAbs (89), and most have documented increased accumulation of the respective isotope in association with histologic rejection. The requirements for costly antibodies and radiological materials as well as the lack of consensus on specific molecular targets important for detect-ing rejection however have precluded these approaches for routine use. Work by Suzuki et al. and others have focused on assessing upregulation of cytokines (e.g., IL-2, IL-4) and their transcripts (e.g., IFN mRNA) in infiltrating cells during rejection in murine HHTx grafts (7, 90), though the majority of studies suggest that these techniques be used as an adjunct to histology.
Ultrasound and Related Applications
The current state of conventional echocardiography and the novel high-frequency ultrasound biomicroscopy (UBM) modality to image acutely rejecting HHTx cardiac grafts non-invasively is summarized in Table I. The recent development of gas-filled, lipid-based antibody-conjugated microbubbles for binding cellular and biochemical targets important in graft rejection has proposed myocardial contrast echocardiography as an exciting and promising method of detection in experimental and clinical settings (91). Recently, ultrasound imaging of rat HHTx grafts following injection of microbubbles targeted to ICAM-1 illustrated the ability of adhered bubbles to induce significantly increased myocardial video-intensity in rejecting versus control grafts (76). Microbubbles are currently being tested for UBM applications (92).
Diastolic and Systolic Dysfunction
Previous studies on murine HHTx grafts indicate that both the left and right atria do not participate in atrial filling and thus are not subsequently involved in ventricular filling during diastole (14, 77). However, the relaxation time constant (TE) of the LV pressure fall has been used to evaluate LV diastolic dysfunction during allograft rejection in rats (93) and was reported to be prolonged in rejecting grafts versus control; the authors suggested this finding resulted from impaired myocardial relaxation due to decreased myocardial blood flow and increased LV end-diastolic pressure. Other studies have utilized maximum rate of LV pressure rise (dP/tmax) though the data in rat HHTx allografts has yielded conflicting results (94, 95). The validity of assessing peak systolic and diastolic LV pressures in rat HHTx grafts indicate that both quantities decrease significantly in allografts on day 5 PTx, but are unchanged in isografts (93). However, these measurements require implantation of a balloon in the graft to measure pressure-volume relations.
Though clinically parameters of systolic function have proved to be of limited use (96), inferior to diastolic changes (97), and not rejection-specific, significant decreases in % ejection fraction and stroke volume have been associated with histologic rejection (98). In rat HHTx allografts, diminished cardiac output and stroke work after isoproterenol treatment was found on day 3 PTx (99). Furthermore, studies in HHTx murine grafts indicate a diminishing trend in %EF and %FS in allografts from days 3 to 5 PTx (77). In a recent study employing UBM-Doppler by Zhou et al., left ventricular %FS was found to increase significantly in the long-term, from day 14 to 50 in isografts (14). No parallel study has been reported for allografts.
Studies in rat HHTx models have shown a marked decreased in myocardial tissue blood flow as assessed by the hydrogen-clearance method in day 3 and 5 allografts, whereas it remained stable in isografts (93). Using UBM-Doppler and M-mode analyses, Zhou et al. showed that after 7 days PTx in murine allografts, coronary blood flow velocities were significantly diminished, whereas it significantly increased from day 1 to 5 and remained consistent after 2 weeks post-implantation in isografts (14), thus proposing a novel, non-invasive method for detecting allograft rejection relatively early in mice. The same study also characterized a previously undocumented Doppler waveform of coronary flow in murine grafts, showing the complex interaction between the recipient and donor cardiac cycles.
Tricuspid regurgitation is common in clinical orthotopic grafts (due to elevated pulmonary vascular resistance) (100) but does not seem to be applicable in the mouse model. The right atrium and ventricle are under conditions of low pressure due to non-loading conditions and atrophy (73), inevitably resulting in right atrial and ventricular collapse. Furthermore, Zhou et al. previously showed in murine HHTx isografts that tricuspid and pulmonary UBM-Doppler waveforms are small in amplitude and variable in waveform, thus precluding these measurements as reliable parameters of evaluating rejection (14). The study also characterized mitral and aortic regurgitation in isograft control studies, which showed high regurgitant jets PTx, with consistently high values (>200 cm/s) achieved in isografts after two weeks post-implantation.
Serial echocardiography detected a significant increase in LV posterior wall thickness and conversely, a decrease in LV end-diastolic diameter in rejecting murine allografts from days 0-5 PTx versus isografts (77). Unfortunately, the poor resolution at lower frequencies and the high inter- and intra-observer variability have limited interpretation and applicability of these findings. Furthermore, this observation should be taken cautiously, since ventricular atrophy due to the non-loading nature of the graft can result in decreased myocardial wall thicknesses in isografts (101, 102). Utilizing high frequency echocardiography (UBM, ~30 MHz), Zhou et al. found LV anterior wall thicknesses were consistent throughout the post-transplantation period in isografts, but posterior wall thicknesses gradually decreased and the LV chamber dimensions were reduced (14), likely due to atrophy and low filling pressures. It is anticipated that a comparison study will be published for allografts.
The heterotopic mouse model is an indispensable tool in experimental cardiac transplantation. It combines the advantages of murine studies with a well-established model of fully-vascularized organ transplantation. It is likely that in the boom of the genomics and proteomics era, our understanding of molecular and biochemical mechanisms of graft tolerance and acceptance will be enhanced with the increasing variety of genetically inbred murine strains. Consequently, the need for a reliable method for assessing graft status following transplant will likely continue to be explored, though mouse echocardiography seems to be most promising since it can be performed quickly, is non-invasive, and provides a wealth of information on graft physiology, haemodynamics and morphology.
Acknowledgements: The author would like to thank Dr. Lori West and the rest of the West Lab at the University of Alberta, Canada, Dr. Lee Adamson at Mount Sinai Hospital, Toronto, Canada as well as researchers at the Mouse Imaging Centre in Toronto, Canada, namely Dr. Yu-qing Zhou and Professor Henkelman.
Ramy obtained both his Honours Bachelor of Science (2004) and Master of Science (2007) from the University of Toronto, Canada, the latter from work at The Hospital for Sick Children, Toronto. He completed his medical training at Sydney Medical School, Australia (2010) and is a junior doctor at St George Hospital, a large and busy teaching centre in Sydney’s South East. He has published a small number of publications in the area of murine (Ultra Med and Biol, Jun 2007;33(6):870-9) and clinical cardiac transplantation (Hypothesis 4(1):19-27 (2006)) as well as authored one book in the field entitled ‘Seeing The Transplanted Mouse Heart Like Never Before’ (ISBN Number: 3836487381). He’s presented at national conferences and has dozens of abstracts. Ramy’s current interest lies in obesity medicine and, to that end, is completing a retrospective study on the optimal metabolic rehabilitation of Type II Diabetics at Concord Repatriation General Hospital, a tertiary teaching hospital of the University of Sydney. Ramy recently married a beautiful Australian and enjoys Sydney’s beaches whenever he can.
1. Cramer DV, Podesta LG, Makowska L. Hand-book of Animal Models in Transplantation Research. Boca Raton, Florida, USA: CRC Press Inc.; 1994.
2. Cai Y, Tang XD, Zhou PJ. A combination of anergic cells’ adoptive transfer and rapamycin therapy prolongs cardiac allograft survival in mice. ScandJ Immunol. 2005;61(3):266-73.
3. Levi DS, DeConde AS, Fishbein MC, Burch C, Alejos JC, Wetzel GT. The yield of surveillance endomyocardial biopsies as a screen for cellular rejection in pediatric heart transplant patients. PediatrTransplant. 2004;8(1):22-8.
4. Hofmann B, Tao K, Mai L, West LJ. Acceptance of related and unrelated cardiac allografts in neonatally tolerized mice is cardio-specific and transferable by regulatory CD4+ T cells. J Heart Lung Transplant. 2004;23(9):1069-76.
5. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation. 2004;77(9):1319-26.
6. Fan X, Ang A, Pollock-Barziv SM, Dipchand AI, Ruiz P, Wilson G, et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. NatMed. 2004;10(11):1227-33.
7. Wang H, Hosiawa KA, Min W, Yang J, Zhang X, Garcia B, et al. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol. 2003;171(7):3823-36.
8. Pietra BA, Gill RG. Immunobiology of cardiac allograft and xenograft transplantation. SeminThorac Cardiovasc Surg PediatrCard Surg Annu. 2001;4:123-57.:123-57.
9. Boucek MM, Mathis CM, Boucek RJ, Jr., Hodgkin DD, Kanakriyeh MS, McCormack J, et al. Prospective evaluation of echocardiography for primary rejection surveillance after infant heart transplantation: comparison with endomyocardial biopsy. J Heart Lung Transplant. 1994;13(1 Pt 1):66-73.
10. Abbott CP, Lindsey ES, Creech O, Jr., Dewitt CW. A Technique for Heart Transplantation in the Rat. ArchSurg. 1964;89:645-52.:645-52.
11. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg. 1969;57(2):225-9.
12. Heron I. A technique for accessory cervical heart transplantation in rabbits and rats. Acta Pathol MicrobiolScand[A]. 1971;79(4):366-72.
13. Corry RJ, Winn HJ, Russell PS. Heart transplantation in congenic strains of mice. Transplant Proc. 1973;5(1):733-5
14. Zhou YQ, Bishay R, Feintuch A, Tao K, Golding F, Zhu W, et al. Morphological and functional evaluation of murine heterotopic cardiac grafts using ultrasound biomicroscopy Ultrasound MedBiol. 2007;33(6):870-9.
15. Niimi M. The technique for heterotopic cardiac transplantation in mice: experience of 3000 operations by one surgeon. J Heart Lung Transplant. 2001;20(10):1123-8.
16. Silber S. The Rat in Microsurgery. Baltimore, MD, USA: Williams & Wilkins; 1979.
17. Mao M, Liu X, Tian J, Yan S, Lu X, Gueler F, et al. A novel and knotless technique for heterotopic cardiac transplantation in mice. JHeart Lung Transplant. 2009;28(10):1102-6.
18. Wang Q, Liu Y, Li XK. Simplified technique for heterotopic vascularized cervical heart trans-plantation in mice. Microsurgery. 2005;25(1): 76-9.
19. Stalder M TT, Lam TT, Chan MC, Berry GJ, Borie DC, Morris RE. Improved assessment of graft function by echocardiography in cynomolgus monkey recipients of hDAF-transgenic pig cardiac xenografts.: J Heart Lung Transplant.; 2005. p. 215-21.
20. Sawyer GJ, Gustafsson K, Fabre JW. Vascularised mouse-to-rat heart grafts: an unexpectedly difficult model of xenotransplantation. Transplant Proc. 1995;27(1):309.
21. Jones ND, Turvey SE, Van Maurik A, Hara M, Kingsley CI, Smith CH, et al. Differential Susceptibility of Heart, Skin, and Islet Allografts to T Cell-Mediated Rejection. The Journal of Immunology. 2001;166(4):2824-30.
22. Medawar PB. The behaviour and fate of skin autografts and skin homografts in rabbits: A report to the War Wounds Committee of the Medical Research Council. J Anat. 1944;78(Pt 5):176-99.
23. Cho SI, Marcus FS, Kountz SL. A new model for study of allograft rejection in the rat: use of skin with an intact vascular pedicle. I. Transplantation. 1972;13(5):486-92.
24. Steinmuller D. Skin allograft rejection by stable hematopoietic chimeras that accept organ allografts sill is an enigma. Transplantation. 2001; 72(1):8-9.
25. Larsen CP, Steinman RM, Witmer-Pack M, Hankins DF, Morris PJ, Austyn JM. Migration and maturation of Langerhans cells in skin trans-plants and explants. J ExpMed. 1990;172(5): 1483-93.
26. Sun J, Sheil AG, Wang C, Wang L, Rokahr K, Sharland A, et al. Tolerance to rat liver allografts: IV. Acceptance depends on the quantity of donor tissue and on donor leukocytes. Transplantation. 1996;62(12):1725-30.
27 Figueiredo JL, Nahrendorf M, Sosnovik DE, Weissleder R. MRI of a novel murine working heart transplant model. CircHeart Fail. 2009;2(3):272-4. .
28. Hasegawa T, Bouis D, Liao H, Visovatti SH, Pinsky DJ. Ecto-5’ nucleotidase (CD73)-mediated adenosine generation and signaling in murine cardiac allograft vasculopathy. Circ Res. 2008 Dec 5;103(12):1410-21.
29. King CL, Devitt JJ, Lee TD, Hancock Friesen CL. Neutrophil mediated smooth muscle cell loss precedes allograft vasculopathy. J Cardiothorac Surg. 2010;5:52.
30. Hasegawa T, Iwanaga K, Hultquist DE, Liao H, Visovatti SH, Pinsky DJ. Suppression of nitrosative and oxidative stress to reduce cardiac allograft vasculopathy. Am J Physiol Heart Circ Physiol. 2009 Apr;296(4):H1007-16.
31. Bernhard A, Konertz W. Experimental heart transplantation. J Thorac Cardiovasc Surg. 1983;86 (2):314-5.
32. Hau J, Van Hoosier GL. Handbook of Laboratory Animal Science. Boca Raton, Florida, USA: CRC Press Inc.; 200.3.
33. Konertz W, Semik M, Bernhard A. Heart, lung and heart-lung transplantation in rats. J Heart Transplant. 1985;4(4):426-30.
34. Sucher R, Gehwolf P, Kaier T, Hermann M, Maglione M, Oberhuber R, et al. Intracellular signaling pathways control mitochondrial events associated with the development of ischemia/ reperfusion-associated damage. TransplInt. 2009;22(9):922-30.
35. Kosuge H, Haraguchi G, Koga N, Maejima Y, Suzuki J, Isobe M. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation. 2006;113(22):2613-22.
36. Tao R, Wang L, Chen CH, Wang SH, Demarco RA, Lotze MT, et al. Mechanistic insights into achievement of cardiac allograft long-term survival by treatment with immature dendritic cells and sub-dose sirolimus. J Heart Lung Transplant. 2006;25(3):310-9.
37. Wang Z, Castellaneta A, De Creus A, Shufesky WJ, Morelli AE, Thomson AW. Heart, but not skin, allografts from donors lacking Flt3 ligand exhibit markedly prolonged survival time. J Immunol. 2004;172(10):5924-30.
38. Smith JA, Mottram PL, Mirisklavos A, Mason A, Dumble LJ, Clunie GJ. The effect of operative ischemia in murine cardiac transplantation: isograft control studies. Surgery. 1987;101(1):86-90.
39. Makowka L, Zerbe TR, Chapman F, Qian SG, Sun H, Murase N, et al. Prolonged rat cardiac preservation with UW lactobionate solution. Transplant Proc. 1989;21(1 Pt 2):1350-2.
40. McGregor CG, McCallum HM, Hannan J, Smith AF, Muir AL. Long-term effects of cold cardioplegic myocardial protection in the rat. J Thorac Cardiovasc Surg. 1984;87(6):913-9.
41. McGregor CG, Hannan J, Smith AF, Muir AL, Wheatley DJ. A study of cold cardioplegic myocardial protection in rats: an experimental model using the uptake of technetium 99m pyrophosphate and enzyme activity as parameters of injury. Cardiovasc Res. 1983;17(2):70-4.
42. Soto PF, Jia CX, Carter YM, Rabkin D, Starr JP, Amirhamzeh MM, et al. Effect of improved myocardial protection on edema and diastolic properties of the rat left ventricle during acute allograft rejection. J Heart Lung Transplant. 1998;17(6):608-16.
43. Blanchard JM, Pollak R. Techniques for perfusion and storage of heterotopic heart transplants in mice. Microsurgery. 1985;6(3):169-74.
44. Tanaka M, Gunawan F, Terry RD, Inagaki K, Caffarelli AD, Hoyt G, et al. Inhibition of heart transplant injury and graft coronary artery disease after prolonged organ ischemia by selective protein kinase C regulators. J ThoracCardiovascSurg. 2005;129(5):1160-7.
45. Tanaka M, Mokhtari GK, Terry RD, Gunawan F, Balsam LB, Hoyt G, et al. Prolonged cold ischemia in rat cardiac allografts promotes ischemia-reperfusion injury and the development of graft coronary artery disease in a linear fashion. J Heart Lung Transplant. 2005;24(11):1906-14.
46. Galinanes M, Hearse DJ. Metabolic, functional, and histologic characterization of the heterotopically transplanted rat heart when used as a model for the study of long-term recovery from global ischemia. J Heart Lung Transplant. 1991;10(1 Pt 1):79-91.
47. Fan X, Tyerman K, Ang A, Koo K, Parameswaran K, Tao K, et al. A novel tool for B-cell tolerance research: characterization of mouse alloantibody development using a simple and reliable cellular ELISA technique. Transplant Proc. 2005;37(1):29-31.
48. Akashi S, Sho M, Kashizuka H, Hamada K, Ikeda N, Kuzumoto Y, et al. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation. 2005;80(3):378-84.
49. West LJ, Morris PJ, Wood KJ. Neonatally induced transplantation tolerance to primarily vascularised cardiac allografts is not donor-specific. Transplant Proc. 1995;27(1):184-5.
50. Honjo K, Xu X, Bucy RP. CD4+ T-cell receptor transgenic T cells alone can reject vascularized heart transplants through the indirect pathway of alloantigen recognition. Transplantation. 2004;77(3):452-5.
51. Grazia TJ, Pietra BA, Johnson ZA, Kelly BP, Plenter RJ, Gill RG. A two-step model of acute CD4 T-cell mediated cardiac allograft rejection. J Immunol. 2004;172(12):7451-8.
52. Oluwole SF, Oluwole OO, DePaz HA, Adeyeri AO, Witkowski P, Hardy MA. CD4+CD25+ regulatory T cells mediate acquired transplant tolerance. TransplImmunol. 2003;11(3-4):287-93.
53. White WL, Zhang YL, Shelby J, Trautman MS, Perkins SL, Hammond EH, et al. Myocardial apoptosis in a heterotopic murine heart transplantation model of chronic rejection and graft vasculopathy. J Heart Lung Transplant. 1997;16(2):250-5.
54. Christopher K, Mueller TF, DeFina R, Liang Y, Zhang J, Gentleman R, et al. The graft response to transplantation: a gene expression profile analysis. Physiol Genomics. 2003;15(1):52-64.
55. Wehner JR, Morrell CN, Rodriguez ER, Fairchild RL, Baldwin WM, III. Immunological challenges of cardiac transplantation: the need for better animal models to answer current clinical questions. JClinImmunol. 2009;29(6):722-9.
56 Shimmura H, Tanabe K, Habiro K, Abe R, Toma H. Combination effect of mycophenolate mofetil with mizoribine on cell proliferation assays and in a mouse heart transplantation model. Transplantation. 2006;82(2):175-9.
57. Mitsuhashi N, Fischer-Lougheed J, Shulkin I, Kleihauer A, Kohn DB, Weinberg KI, et al. Tolerance induction by lentiviral gene therapy with a nonmyeloablative regimen. Blood. 2006;107(6):2286-93.
58. Kosuge H, Suzuki J, Gotoh R, Koga N, Ito H, Isobe M, et al. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation. 2003;75(8):1374-9.
59. Bonham CA, Peng L, Liang X, Chen Z, Wang L, Ma L, et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol. 2002;169(6):3382-91.
60. Nguyen TK, Nilakantan V, Felix CC, Khanna AK, Pieper GM. Beneficial effect of alpha-tocopheryl succinate in rat cardiac transplants. J Heart Lung Transplant. 2006;25(6):707-15.
61. Isobe M, Ihara A. Tolerance induction against cardiac allograft by anti-ICAM-1 and anti-LFA-1 treatment: T cells respond to in vitro allostimulation. Transplant Proc. 1993;25(1 Pt 2):1079-80.
62. Suzuki J, Isobe M, Izawa A, Takahashi W, Yamazaki S, Okubo Y, et al. Differential Th1 and Th2 cell regulation of murine cardiac allograft acceptance by blocking cell adhesion of ICAM- 1/LFA-1 and VCAM-1/VLA-4. TransplImmunol. 1999;7(1):65-72.
63. Cramer DV, Chapman FA, Jaffee BD, Eiras- Hreha G, Yasunaga C, Wu GD, et al. The effect of a new immunosuppressive drug, brequinar sodium, on concordant hamster-to-rat cardiac xenografts. Transplant Proc. 1992;24(2):720-1.
64. Steinbruchel DA, Madsen HH, Nielsen B, Kemp E, Larsen S, Koch C. The effect of combined treatment with total lymphoid irradiation, cyclosporin A, and anti-CD4 monoclonal antibodies in a hamster-to-rat heart transplantation model. Transplant Proc. 1991;23(1 Pt 1):579-80.
65. Filipponi F, Michel A, Houssin D. Prolongation of guinea pig-to-rat xenograft survival with BN 52063, a specific antagonist of platelet-activating factor. ItalJ Surg Sci. 1989;19(4):325-9.
66. June BW, Felix NJ, Griffiths R, Zhang J, Wang B, Piskurich JF, et al. Prolonged survival of class II transactivator-deficient cardiac allografts. Transplantation. 2002;74(9):1341-8.
67. Shimizu K, Schonbeck U, Mach F, Libby P, Mitchell RN. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol. 2000;165(6):3506-18.
68. Mottram PL, Raisanen-Sokolowski A, Glysing- Jensen T, Stein-Oakley AN, Mary E. Cardiac Allografts from IL-4 Knockout Recipients: Assessment of Transplant Arteriosclerosis and Peripheral Tolerance. The Journal of Immunology. 1998;161(2):602-9.
69. Christopher K, Liang Y, Mueller TF, DeFina R, He H, Haley KJ, et al. Analysis of the major histocompatibility complex in graft rejection revisited by gene expression profiles. Transplantation. 2004;78(6):788-98.
70. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation. 1973;16(4):343-50.
71. Abbott CP, Dewitt CW, Creech O, Jr. The transplanted rat heart: histologic and electrocardiographic changes. Transplantation. 1965;3:432-45.:432-45.
72. Abbott CP, Creech O, Jr., Dewitt CW. Histologic and electrocardiographic changes of the transplanted rat heart. Surg Forum. 1964;15:253-5.:253-5.
73. Mottram PL, Smith JA, Mason A, Mirisklavos A, Dumble LJ, Clunie GJ. Electrocardiographic monitoring of cardiac transplants in mice. CardiovascRes. 1988;22(5):315-21.
74. Affleck DG, Bull DA, Albanil A, Shao Y, Brady J, Karwande SV, et al. Interleukin-18 production following murine cardiac transplantation: correlation with histologic rejection and the induction of INF-gamma. J Interferon Cytokine Res. 2001;21(1):1-9.
75. Caves PK, Stinson EB, Billingham ME, Rider AK, Shumway NE. Diagnosis of human cardiac allograft rejection by serial cardiac biopsy. J Thorac Cardiovasc Surg. 1973;66(3):461-6.
76. Weller GE, Lu E, Csikari MM, Klibanov AL, Fischer D, Wagner WR, et al. Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to intercellular adhesion molecule-1. Circulation. 2003;108(2):218-24.
77. Scherrer-Crosbie M, Glysing-Jensen T, Fry SJ, Vancon AC, Gadiraju S, Picard MH, et al. Echocardiography improves detection of rejection after heterotopic mouse cardiac transplantation. J Am SocEchocardiogr. 2002;15(10 Pt 2):1315-20.
78. Nakhleh RE, Jones J, Goswitz JJ, Anderson EA, Titus J. Correlation of endomyocardial biopsy findings with autopsy findings in human cardiac allografts. J Heart Lung Transplant. 1992;11(3 Pt 1):479-85.
79. Superina RA, Peugh WN, Wood KJ, Morris PJ. Assessment of primarily vascularized cardiac allografts in mice. Transplantation. 1986;42(2):226-7.
80. Bishop S. Cardiovascular Research. New York: Academic Press; 1980.
81. Wada T, Ono K, Hadama T, Uchida Y, Shimada T, Arita M. Detection of acute cardiac rejection by analysis of heart rate variability in het-erotopically transplanted rats. J Heart Lung Transplant. 1999;18(6):499-509.
82. Haug CE, Shapiro JI, Chan L, Weil R, III. P-31 nuclear magnetic resonance spectroscopic evaluation of heterotopic cardiac allograft rejec-tion in the rat. Transplantation. 1987;44(2):175-8.
83. Yang XP, Liu YH, Rhaleb NE, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. AJP – Heart and Circulatory Physiology. 1999;277(5):H1967-H74.
84. Kanno S, Wu YJ, Lee PC, Dodd SJ, Williams M, Griffith BP, et al. Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation. 2001;104(8):934-8.
85. Wu YJ, Sato K, Ye Q, Ho C. MRI investigations of graft rejection following organ transplantation using rodent models. Methods Enzymol. 2004;386:73-105.:73-105.
86. Scherrer-Crosbie M, Thibault HB. Echocardiography in translational research: of mice and men. JAmSocEchocardiogr. 2008;21 (10):1083-92.
87. Ohtani H, Strauss HW, Southern JF, Tamatani T, Miyasaka M, Sekiguchi M, et al. Intercellular adhesion molecule-1 induction: a sensitive and quantitative marker for cardiac allograft rejection. J Am Coll Cardiol. 1995;26(3):793-9.
88. Isobe M, Narula J, Southern JF, Strauss HW, Khaw BA, Haber E. Imaging the rejecting heart. In vivo detection of major histocompatibility complex class II antigen induction. Circulation. 1992;85(2):738-46.
89. Isobe M, Haber E, Khaw BA. Early detection of rejection and assessment of cyclosporine therapy by 111In antimyosin imaging in mouse heart allografts. Circulation. 1991;84(3):1246-55.
90. Suzuki J, Isobe M, Yamazaki S, Horie S, Okubo Y, Sekiguchi M. Sensitive diagnosis of cardiac allograft rejection by detection of cytokine transcription in situ. Cardiovasc Res. 1998;40(2):307-13.
91. Lindner JR. Microbubbles in medical imaging: current applications and future directions. NatRevDrug Discov. 2004;3(6):527-32.
92. Goertz DE, Needles A, Burns PN, Foster FS. High-frequency, nonlinear flow imaging of micro-bubble contrast agents. IEEE TransUltrason- FerroelectrFreqControl. 2005;52(3):495-502.
93. Szabo G, Batkai S, Dengler TJ, Bahrle S, Stumpf N, Notmeyer W, et al. Systolic and diastolic properties and myocardial blood flow in the heterotopically transplanted rat heart during acute cardiac rejection. World J Surg. 2001;25(5):545-52.
94. Dambrin C, El Feghaly M, Abbal M, Glock Y, Durand D, Fournial G, et al. A new rejection criteria in the heterotopically placed rat heart by non-invasive measurement of Dp/Dtmax. J Heart Lung Transplant. 1999;18(6):524-31.
95. Yoshida S, Takeuchi K, del Nido PJ, Ho C. Diastolic dysfunction coincides with early mild transplant rejection: in situ measurements in a heterotopic rat heart transplant model. J Heart Lung Transplant. 1998;17(11):1049-56.
96. Vivekananthan K, Kalapura T, Mehra M, Lavie C, Milani R, Scott R, et al. Usefulness of the combined index of systolic and diastolic myocardial performance to identify cardiac allograft rejection. Am J Cardiol. 2002;90(5):517-20.
97. Burgess MI, Bhattacharyya A, Ray SG. Echocardiography after cardiac transplantation. J Am SocEchocardiogr. 2002;15(9):917-25.
98. Sade LE, Sezgin A, Ulucam M, Taymaz S, Simsek V, Tayfun E, et al. Evaluation of the potential role of echocardiography in the detection of allograft rejection in heart transplant recipients. Transplant Proc. 2006;38(2):636-8.
99. DiSesa VJ, Masetti P, Diaco M, Schoen FJ, Marsh JD, Cohn LH. The mechanism of heart failure caused by cardiac allograft rejection. J ThoracCardiovascSurg. 1991;101(3):446-9.
100. Anderson CA, Shernan SK, Leacche M, Rawn JD, Paul S, Mihaljevic T, et al. Severity of intraoperative tricuspid regurgitation predicts poor late survival following cardiac transplantation. AnnThoracSurg. 2004;78(5):1635-42.
101. Spencer AU, Hart JP, Cabreriza SE, Rabkin DG, Weinberg AD, Spotnitz HM. Aortic regurgitation in the heterotopic rat heart transplant: effect on ventricular remodeling and diastolic function. J Heart Lung Transplant. 2003;22(8):937-45.
102. Welsh DC, Dipla K, McNulty PH, Mu A, Ojamaa KM, Klein I, et al. Preserved contractile function despite atrophic remodeling in unloaded rat hearts. AJP – Heart and Circulatory Physiology. 2001;281(3):H1131-H6.